PPARA and cardiomyopathy: In summary, our study allows to draw several important conclusions: (a) The heart is highly responsive to the treatment with pan-PPAR agonist, BF, which at a clinically relevant dose effectively prevents the development of cardiomyopathy in the mouse model of BTHS.